Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;21(11):1976-81.
doi: 10.1038/mt.2013.226.

Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy

Terence R Flotte  1
Affiliations

Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy

Terence R Flotte. Mol Ther. 2013 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time line of major milestones in AAV biology and vectorology. The 47 years between the discovery of adeno-associated virus (AAV) and the licensure of Glybera are depicted in three intervals, each approximately 15 years long (1965–1982, 1982–1997, and 1997–2012), with each individually marked segment representing approximately 5 years. IM, intramuscular; ITR, inverted terminal repeat.
Figure 2
Figure 2
Figure from a 1969 publication on adeno-associated virus (AAV) biology. The illustration depicts an AAV's unusual property of being packaged as single-stranded DNA with equal proportions of plus and minus sense strands. Such studies spurred interest in AAV long before the advent of human gene therapy. Reprinted with permission from ref. .
Figure 3
Figure 3
Evidence of efficacy in a human gene therapy trial. The trial used a rAAV2-RPE65 vector to treat patients with the autosomal recessive blinding disorder Leber's congenital amaurosis (LCA). The several-log10-fold change in light sensitivity in the injected portions of the treated retinas (indicated by stars) of three patients (P1, P2, P3) indicates benefit to visual function in these patients. On the opposite side of the panel are the light-sensitivity results from the contralateral eyes (P1, P2, P3) and from an untreated patient (RPE65-LCA). Reprinted with permission from ref. .
Figure 4
Figure 4
The biodiversity of primate-derived adeno-associated virus (AAV) genomic variants. The variants (shown within clades here), which were identified in in the landmark 2004 article by Gao et al.,98 may provide many new potential capsid vehicles for therapeutic gene transfer in the future. Reprinted with permission from ref. .
See this image and copyright information in PMC

References

    1. Burnett JR., and, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther . 2009;11:681–691. - PubMed
    1. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB.et al. (2013Lessons learned from the clinical development and market authorization of Glybera Hum Gene Ther Clin Dev 2455–64. - PMC - PubMed
    1. Ylä-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012;20:1831–1832. - PMC - PubMed
    1. Blacklow NR, Hoggan MD., and, Rowe WP. Isolation of adenovirus-associated viruses from man. Proc Natl Acad Sci USA. 1967;58:1410–1415. - PMC - PubMed
    1. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB., and, Rowe WP. Epidemiology of adenovirus-associated virus infection in a nursery population. . Am J Epidemiol. 1968;88:368–378. - PubMed

Publication types